Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Acquisitions (2022 - 2025)

Maravai Lifesciences Holdings has reported Acquisitions over the past 3 years, most recently at $362000.0 for Q2 2025.

  • Quarterly results put Acquisitions at $362000.0 for Q2 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $19.0 million (changed N/A YoY), and the annual figure for FY2025 was $19.0 million, changed.
  • Acquisitions for Q2 2025 was $362000.0 at Maravai Lifesciences Holdings, down from $18.6 million in the prior quarter.
  • Over the last five years, Acquisitions for MRVI hit a ceiling of $238.8 million in Q1 2022 and a floor of -$109000.0 in Q2 2023.
  • Median Acquisitions over the past 3 years was $9.5 million (2025), compared with a mean of $54.6 million.
  • Peak annual rise in Acquisitions hit 70.8% in 2023, while the deepest fall reached 70.8% in 2023.
  • Maravai Lifesciences Holdings' Acquisitions stood at $133000.0 in 2022, then crashed by 181.95% to -$109000.0 in 2023, then surged by 432.11% to $362000.0 in 2025.
  • The last three reported values for Acquisitions were $362000.0 (Q2 2025), $18.6 million (Q1 2025), and -$109000.0 (Q2 2023) per Business Quant data.